129 related articles for article (PubMed ID: 17122866)
1. Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy.
Tokita K; Maki K; Tadokoro J; Nakamura Y; Arai Y; Sasaki K; Eguchi-Ishimae M; Eguchi M; Mitani K
Leukemia; 2007 Jan; 21(1):190-2. PubMed ID: 17122866
[No Abstract] [Full Text] [Related]
2. Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.
Bastie JN; Garcia I; Terré C; Cross NC; Mahon FX; Castaigne S
Haematologica; 2004 Oct; 89(10):1263-4. PubMed ID: 15477214
[TBL] [Abstract][Full Text] [Related]
3. Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.
Cavazzini F; Bardi A; Ciccone M; Rigolin GM; Gorello P; La Starza R; Mecucci C; Cuneo A
Cancer Genet Cytogenet; 2009 Oct; 194(1):67-9. PubMed ID: 19737658
[No Abstract] [Full Text] [Related]
4. Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
Schafhausen P; Dierlamm J; Bokemeyer C; Bruemmendorf TH; Bacher U; Zander AR; Schnittger S; Hochhaus A
Cancer Genet Cytogenet; 2009 Feb; 189(1):63-7. PubMed ID: 19167615
[No Abstract] [Full Text] [Related]
5. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
6. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
7. Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion.
Li Z; Yang R; Zhao J; Yuan R; Lu Q; Li Q; Tse W
Pediatr Blood Cancer; 2011 Mar; 56(3):463-6. PubMed ID: 21072821
[TBL] [Abstract][Full Text] [Related]
8. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.
Medves S; Duhoux FP; Ferrant A; Toffalini F; Ameye G; Libouton JM; Poirel HA; Demoulin JB
Leukemia; 2010 May; 24(5):1052-5. PubMed ID: 20164854
[No Abstract] [Full Text] [Related]
9. Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate.
Yalamanchili K; Liu D; Seiter K
Leukemia; 2007 Mar; 21(3):577-8. PubMed ID: 17230224
[No Abstract] [Full Text] [Related]
10. A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate.
Wittman B; Horan J; Baxter J; Goldberg J; Felgar R; Baylor E; Cromwell B; Cross N; Bennett JM
Leuk Res; 2004 May; 28 Suppl 1():S65-9. PubMed ID: 15036944
[TBL] [Abstract][Full Text] [Related]
11. Sustained response to low-dose imatinib mesylate in a patient with chronic myelomonocytic leukemia with t(5;12)(q33;p13).
Shin J; Kim M; Kim DB; Yeom JO; Lee HJ; Cho SG
Acta Haematol; 2008; 119(1):57-9. PubMed ID: 18268406
[No Abstract] [Full Text] [Related]
12. Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML).
Hackanson B; Rückert A; Lübbert M
Eur J Haematol; 2009 Dec; 83(6):611-2. PubMed ID: 19682063
[No Abstract] [Full Text] [Related]
13. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
Levine RL; Wadleigh M; Sternberg DW; Wlodarska I; Galinsky I; Stone RM; DeAngelo DJ; Gilliland DG; Cools J
Leukemia; 2005 Jan; 19(1):27-30. PubMed ID: 15496975
[TBL] [Abstract][Full Text] [Related]
14. A novel specific signature of pediatric MOZ-CBP acute myeloid leukemia.
Serravalle S; Melchionda F; Astolfi A; Libri V; Masetti R; Pession A
Leuk Res; 2010 Nov; 34(11):e292-3. PubMed ID: 20630590
[No Abstract] [Full Text] [Related]
15. Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation.
Nanri T; Matsuno N; Kawakita T; Mitsuya H; Asou N
Leukemia; 2005 Sep; 19(9):1673-5. PubMed ID: 16049512
[No Abstract] [Full Text] [Related]
16. [Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis].
Takahari D; Matsunaga T; Fujimi A; Kikuchi T; Seki R; Tanaka I; Takemoto N; Akiyama T; Sato T; Terui T; Kogawa K; Kato J; Kura T; Maeda T; Niitsu Y
Rinsho Ketsueki; 2002 Oct; 43(10):924-30. PubMed ID: 12462028
[TBL] [Abstract][Full Text] [Related]
17. A novel cytogenetic aberration found in stem cell leukemia/lymphoma syndrome.
Shvidel L; Sigler E; Vorst E; Feldberg E; Voskoboinic N; Shtalrid M; Berrebi A
Leukemia; 2008 Mar; 22(3):644-6. PubMed ID: 17928887
[No Abstract] [Full Text] [Related]
18. [Reappearance of t(12;17)-positive primary myelofibrosis following Ph+ CML cell reduction by imatinib].
Araki N; Takimoto R; Fujimi A; Murase K; Araki H; Takahira N; Matsunaga T; Terui T; Kogawa K; Hirayama Y; Kato J; Niitsu Y
Rinsho Ketsueki; 2007 Jun; 48(6):518-23. PubMed ID: 17633103
[TBL] [Abstract][Full Text] [Related]
19. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease.
Curtis CE; Grand FH; Waghorn K; Sahoo TP; George J; Cross NC
Leukemia; 2007 Aug; 21(8):1839-41. PubMed ID: 17508004
[No Abstract] [Full Text] [Related]
20. Successful treatment of advanced idiopathic myelofibrosis with imatinib mesylate.
Stagno F; Consoli C; Mannino F; Guglielmo P; Giustolisi R
Eur J Haematol; 2004 Aug; 73(2):147-8. PubMed ID: 15245516
[No Abstract] [Full Text] [Related]
[Next] [New Search]
